Aethlon Medical Announces Corporate Update at 4pm ET on March 24, 2010
March 02 2010 - 7:00AM
PR Newswire (US)
SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc.
(OTC Bulletin Board: AEMD), the pioneer in developing therapeutic
filtration devices to address infectious disease and cancer,
announced that Jim Joyce, its Chairman and Chief Executive Officer,
will present a corporate update from the NASDAQ Marketsite at the
2010 RedChip New York Equities Conference on March 24, 2010. Mr.
Joyce will address a number of topics, including manufacturing,
research programs and initial commercialization. The presentation
will follow the market close and investors are urged to listen to
the live webcast at: http://www.redchip.com/. (Logo:
http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b) Aethlon
also disclosed that John P. Salvador has been named as Director of
Corporate Communications. Mr. Salvador, an accomplished corporate
communications and investor relations professional, will act as a
liaison with the medical community, candidate patients and
shareholders. Aethlon further disclosed that Mr. Joyce will present
at the LDV Growth and Value Investor Conference, tomorrow, March
3rd and on the 4th at the Sheraton Suites Cypress Place in Fort
Lauderdale, Florida. The presentation will begin at 6:10 pm EST on
both nights. About Aethlon Medical Aethlon Medical, Inc. creates
diagnostic and therapeutic device solutions for infectious disease
and cancer. Our lead product, the Hemopurifier ® is the
first-in-class medical device to selectively capture circulating
viruses and immunosuppressive proteins prior to cell and organ
infection. Human studies have documented the ability of our
Hemopurifier ® to reduce viral load in patients infected with
Hepatitis-C virus (HCV) and the Human Immunodeficiency Virus (HIV).
Our primary clinical and commercialization focus is to establish
the Hemopurifier ® as an adjunct therapy to enhance and
prolong the benefit of traditional infectious disease drug
regimens. The Hemopurifier ® is also a broad-spectrum
treatment candidate against drug resistant bioterror and pandemic
threats. Third party research institutes have verified the
capability of the device to capture Dengue Hemorrhagic Virus, Ebola
Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1
Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed
Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a
model for human Smallpox infection. Our wholly owned subsidiary,
Exosome Sciences, Inc. (ESI) was formed in October of 2009 to
leverage attributes of the Hemopurifier ® in the emerging
exosome research field. ESI seeks to inhibit the immune cell
destruction caused by exosomes secreted by solid tumors, lymphomas,
and leukemia. At present, the capture of immunosuppressive exosomes
secreted from ovarian cancer tumors has been demonstrated invitro.
The preservation of anti-cancer immune cells would likely improve
patient responsiveness to established treatment options, including
immunotherapy and chemotherapy. ESI is also analyzing
exosome-related opportunities to improve early cancer detection and
post-surgery surveillance of tumor growth, as well as approaches to
harvest exosomes for research purposes and potential reintroduction
into patients afflicted with autoimmune conditions such as
Rheumatoid Arthritis and Lupus. Additional information regarding
Aethlon Medical and Exosome Sciences can be accessed online at
http://www.aethlonmedical.com/. Certain of the statements herein
may be forward-looking and involve risks and uncertainties. Such
forward-looking statements involve assumptions, known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without
limitation, the capability of the Hemopurifier ® to reduce
viral loads and other disease conditions or to identify disease
conditions such as cancer, including the ability to capture
exosomes and the impact that potential ability may have on disease
conditions, the Company's ability to raise capital when needed, the
Company's ability to complete the development of its planned
products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the
Company's ability to manufacture its products and provide its
services, the impact of government regulations, patent protection
on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings. Contacts:
RedChip Companies, Inc. Jon Cunningham 1-800-733-2447, Ext. 107
Jon@redchip.com Jim Joyce Chairman, CEO 858.459.7800 x301
jj@aethlonmedical.com John P. Salvador Director of Corporate
Communications 858.459.7800 x307 jps@aethlonmedical.com DATASOURCE:
Aethlon Medical, Inc. CONTACT: Jon Cunningham of RedChip Companies,
Inc., 1-800-733-2447, Ext.107, Jon@redchip.com; or Jim Joyce,
Chairman, CEO, +1-858-459-7800, ext. 301,jj@aethlonmedical.com, or
John P. Salvador, Director of CorporateCommunications,
+1-858-459-7800, ext. 307, jps@aethlonmedical.com, both ofAethlon
Medical, Inc. Web Site: http://www.aethlonmedical.com/
Copyright
Aem Spa (LSE:AEM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aem Spa (LSE:AEM)
Historical Stock Chart
From Sep 2023 to Sep 2024